MedTrace Logo

STEMI and Incretins Treatment

NCT03312179 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2017-10-19

No results posted yet for this study

Summary

ST elevation myocardial infarction (STEMI) patients affected by multivessels coronary artery stenosis, represent a clinical relevant problem. The management and prognosis of these patents are supported by few literature data. Therefore, in this study authors enrolled real world diabetic vs. non diabetic patients admitted for STEMI and associated to multi vessels coronary disease. Then these diabetics were divided in incretin users (6 months of incretin treatment before study enrollment) vs. never incretin users. In these patients authors studied all cause mortality, cardiac mortality, and major adverse cardiac events at 12 months follow up.

Conditions

Interventions

DEVICE

PCI and DES stenting

Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.

DRUG

Incretins

Patients treated before study enrollment by incretin drugs (6 months drugs exposure)

Sponsors & Collaborators

  • University of Campania Luigi Vanvitelli

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-09-01
Completion
2017-10-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03312179 on ClinicalTrials.gov